BrainStorm by UsAgainstAlzheimer's Meryl Comer, UsAgainstAlzheimer's

Rebecca Chopp, Ph.D., built a life around a profession that prized the mind and then was unexpectedly diagnosed with Alzheimer's disease. Hear how Dr. Chopp, former Chancellor of the University of Denver, President of Swarthmore College and Colgate University, and Dean and Professor of Theology at Yale Divinity School, learned to embrace joy after coming to terms with her Alzheimer’s diagnosis.  
Support the show

BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi, Vice-Chair of Neurology at Massachusetts General Hospital, Co-Director of the McCance Center for Brain Health and Professor at Harvard Medical School.  Hear what Dr. Tanzi discovered through his creative collaboration on 4 books with integrative medicine guru, Deepak Chopra, and his action plan "SHIELD" to offset the risk of Alzheimer’s disease.
Support the show

Will 2023 be a boom or bust year for new Alzheimer’s drugs? 
In this episode of BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi, Vice-Chair of Neurology at Massachusetts General Hospital, Co-Director of the McCance Center for Brain Health and Professor at Harvard Medical School.  Dr. Tanzi discusses the promising new drugs in a highly charged scientific environment and how these drugs have opened the door to advancement in the treatment of Alzheimer’s. 
Support the show

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?
In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile.
Support the show

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?
In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at BrainStorm@usagainstalzheimers.org.



Support the show

Rising longevity and the aging of boomers worldwide are radically altering both the demographic landscape and every aspect of our personal, social, financial, and political lives.
 In this episode of BrainStorm, UsAgainstAlzheimer’s National Summit keynote speaker Ken Dychtwald, Founder and CEO of Age Wave, talks about the future of health, medicine, aging, and longevity.  What gero-science breakthroughs are currently at the tipping point and how can we ensure that our health spans and brain spans match our life spans? Dr. Dychtwald is counted among the foremost visionaries and original thinkers in the field and was honored by World Leaders magazine as one the world’s visionary leaders making an impact in 2022.

Do you have feedback or an idea for the podcast? Send us a note at BrainStorm@usagainstalzheimers.org.
Support the show